Javier F. Torres-Roca

Javier F. Torres-Roca

Auto-generated profile, based on publicly available information

Javier F. Torres-Roca

Department of Biostatistics and Biomedical Informatics, Moffitt Cancer Center, Tampa, Florida, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJacob G Scott
Jacob G Scott
ABAnders Berglund
Anders Berglund
MSMichael J Schell
Michael J Schell
IMIvaylo Mihaylov
Ivaylo Mihaylov
WFWilliam J Fulp
William J Fulp
JTJavier F Torres-Roca
Javier F Torres-Roca

1 October 2009 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SESteven A. Eschrich
Steven A. Eschrich
JPJimmy Pramana
Jimmy Pramana
HZHongling Zhang
Hongling Zhang
HZHaiyan Zhao
Haiyan Zhao
DBDavid Boulware
David Boulware
JTJavier F. Torres-Roca
Javier F. Torres-Roca

1 October 2009 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SESteven Eschrich
Steven Eschrich
HZHongling Zhang
Hongling Zhang
HZHaiyan Zhao
Haiyan Zhao
DBDavid Boulware
David Boulware
JLJi-Hyun Lee
Ji-Hyun Lee
JTJavier F. Torres-Roca
Javier F. Torres-Roca

15 September 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SESteven A. Eschrich
Steven A. Eschrich
WFWilliam J. Fulp
William J. Fulp
YPYudi Pawitan
Yudi Pawitan
JFJohn A. Foekens
John A. Foekens
MSMarcel Smid
Marcel Smid
JTJavier F. Torres-Roca
Javier F. Torres-Roca
Purpose: Previously, we developed a radiosensitivity molecular signature [radiosensitivity index (RSI)] that was clinically validated in 3 independent datasets (rectal, esophageal, and head and neck) in 118 patients. Here, we test RSI in radiotherapy (RT)-treated breast cancer patients. Experimental Design: RSI was tested in 2 previously published breast cancer datasets. Patients were treated at the Karolinska University Hospital (n = 159) and Erasmus Medical Center (n = 344). RSI was applied as previously described. Results: We tested RSI in RT-treated patients (Karolinska). Patients predicted to be radiosensitive (RS) had an improved 5-year relapse-free survival when compared with radioresistant (RR) patients (95% vs. 75%, P = 0.0212), but there was no difference between RS/RR patients treated without RT (71% vs. 77%, P = 0.6744), consistent with RSI being RT-specific (interaction term RSI × RT, P = 0.05). Similarly, in the Erasmus dataset, RT-treated RS patients had an improved 5-year distant metastasis-free survival over RR patients (77% vs. 64%, P = 0.0409), but no difference was observed in patients treated without RT (RS vs. RR, 80% vs. 81%, P = 0.9425). Multivariable analysis showed RSI is the strongest variable in RT-treated patients (Karolinska, HR = 5.53, P = 0.0987, Erasmus, HR = 1.64, P = 0.0758) and in backward selection (removal α of 0.10), RSI was the only variable remaining in the final model. Finally, RSI is an independent predictor of outcome in RT-treated ER+ patients (Erasmus, multivariable analysis, HR = 2.64, P = 0.0085). Conclusions: RSI is validated in 2 independent breast cancer datasets totaling 503 patients. Including prior data, RSI is validated in 5 independent cohorts (621 patients) and represents, to our knowledge, the most extensively validated molecular signature in radiation oncology. Clin Cancer Res; 18(18); 5134–43. ©2012 AACR.

15 August 2005 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JTJavier F. Torres-Roca
Javier F. Torres-Roca
SESteven Eschrich
Steven Eschrich
HZHaiyan Zhao
Haiyan Zhao
GBGregory Bloom
Gregory Bloom
JSJimmy Sung
Jimmy Sung
TYTimothy Yeatman
Timothy Yeatman
The development of a successful radiation sensitivity predictive assay has been a major goal of radiation biology for several decades. We have developed a radiation classifier that predicts the inherent radiosensitivity of tumor cell lines as measured by survival fraction at 2 Gy (SF2), based on gene expression profiles obtained from the literature. Our classifier correctly predicts the SF2 value in 22 of 35 cell lines from the National Cancer Institute panel of 60, a result significantly different from chance (P = 0.0002). In our approach, we treat radiation sensitivity as a continuous variable, significance analysis of microarrays is used for gene selection, and a multivariate linear regression model is used for radiosensitivity prediction. The gene selection step identified three novel genes (RbAp48, RGS19, and R5PIA) of which expression values are correlated with radiation sensitivity. Gene expression was confirmed by quantitative real-time PCR. To biologically validate our classifier, we transfected RbAp48 into three cancer cell lines (HS-578T, MALME-3M, and MDA-MB-231). RbAp48 overexpression induced radiosensitization (1.5- to 2-fold) when compared with mock-transfected cell lines. Furthermore, we show that HS-578T-RbAp48 overexpressors have a higher proportion of cells in G2-M (27% versus 5%), the radiosensitive phase of the cell cycle. Finally, RbAp48 overexpression is correlated with dephosphorylation of Akt, suggesting that RbAp48 may be exerting its effect by antagonizing the Ras pathway. The implications of our findings are significant. We establish that radiation sensitivity can be predicted based on gene expression profiles and we introduce a genomic approach to the identification of novel molecular markers of radiation sensitivity.

1 September 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJacob G Scott
Jacob G Scott
GSGeoffrey Sedor
Geoffrey Sedor
PEPatrick Ellsworth
Patrick Ellsworth
JSJessica A Scarborough
Jessica A Scarborough
KAKamran A Ahmed
Kamran A Ahmed
JTJavier F Torres-Roca
Javier F Torres-Roca